3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
3 Phosphoinositide Dependent Protein Kinase 1 Pipeline Drugs Market Report Overview
3 Phosphoinositide Dependent Protein Kinase 1 is an enzyme encoded by the PDPK1 gene, which plays a central role in the transduction of signals from insulin by providing the activating phosphorylation to PKB/AKT1, thus propagating the signal to downstream targets controlling cell proliferation and survival, as well as glucose and amino acid uptake and storage. It negatively regulates the TGF-beta-induced signaling by modulating the association of SMAD3 and SMAD7 with TGF-beta receptor, phosphorylating SMAD2, SMAD3, SMAD4 and SMAD7, preventing the nuclear translocation of SMAD3 and SMAD4 and the translocation of SMAD7 from the nucleus to the cytoplasm in response to TGF-beta.
The PDPK1 – Drugs in Development research report provides a comprehensive overview on the therapeutics under development for PDPK1, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for PDPK1 and features dormant and discontinued projects.
Key Therapy Areas in the PDPK1 Pipeline Drugs Market
In the 3 Phosphoinositide Dependent Protein Kinase 1 pipeline drugs market the key therapy areas are Oncology, and Infectious Disease. Oncology has the maximum number of pipeline products.
PDPK1 Pipeline Drugs Market Analysis, by Therapy Areas
To get more insights on key Therapy Areas, download a free sample report
Key MoA in the 3 Phosphoinositide Dependent Protein Kinase 1 Pipeline Drugs Market
Key MoA in the 3 Phosphoinositide Dependent Protein Kinase 1 Pipeline Drugs Market 3 is Phosphoinositide Dependent Protein Kinase 1 Inhibitor.
PDPK1 Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the PDPK1 pipeline drugs market are oral, and topical. Oral has the highest number of pipeline products.
PDPK1 Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the PDPK1 Pipeline Drugs Market
The key molecule types in the 3 Phosphoinositide Dependent Protein Kinase 1 pipeline drugs market are Small Molecule, and Synthetic Peptide.
PDPK1 Pipeline Drugs Market, by Molecule Type
To get more insights on key molecule types, download a free sample report
Major Companies in the PDPK1 Pipeline Drugs Market
The major companies in the PDPK1 pipeline drugs market are Curacle Co Ltd, PHusis Therapeutics Inc, and Viracta Therapeutics Inc.
PDPK1 Pipeline Drugs Market Overview
Key Therapy Areas | Oncology, and Infectious Disease |
Key Mechanisms of action | Phosphoinositide Dependent Protein Kinase 1 Inhibitor |
Key Routes of Administration | Oral, and Topical |
Key Molecule Types | Small Molecule, and Synthetic Peptide |
Major Companies | Curacle Co Ltd, PHusis Therapeutics Inc, and Viracta Therapeutics Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of PDPK1
- The pipeline guide reviews pipeline therapeutics for PDPK1 by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in PDPK1 therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates PDPK1 therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for PDPK1
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for PDPK1
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding PDPK1 pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key therapy areas in the PDPK1 pipeline drugs market?
In the PDPK1 pipeline drugs market the key therapy areas are Oncology, and Infectious Disease.
-
What are the key mechanisms of action in the PDPK1 pipeline drugs market?
In the PDPK1 pipeline drugs market the key mechanism of action is Phosphoinositide Dependent Protein Kinase 1 Inhibitor.
-
What are the key routes of administration in the PDPK1 pipeline drugs market?
The key routes of administration in the PDPK1 pipeline drugs market are oral, and topical.
-
What are the key molecule types in the PDPK1 pipeline drugs market?
The key molecule types in the PDPK1 pipeline drugs market are Small Molecule, and Synthetic Peptide.
-
What are the major companies in the PDPK1 pipeline drugs market?
In the PDPK1 pipeline drugs market the major companies are Curacle Co Ltd, PHusis Therapeutics Inc, and Viracta Therapeutics Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.